Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Initiation of Midodrine for Ascites in ACLF
NCT07422948Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in acute-on-chronic liver failure (ACLF) and ascites comparing Midodrine+SMT with Placebo+SMT (2 arms). Primary endpoint: Proportion of patients with no ascites at 28 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
midodrine
03
Conditions
acute-on-chronic liver failure (ACLF)ascites
Beyond the preview
Go deeper on NCT07422948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422948.